IRF5 promotes the proliferation of human thyroid cancer cells

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Massimino, Michele ^a   Vigneri, Paolo ^a   Fallica, Manuela ^a   Fidilio, Annamaria ^a   Aloisi, Alessandra ^a   Frasca, Francesco ^a   Manzella, Livia ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cell proliferation; IRF5; Thyroid cancer

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; INTERFERON REGULATORY FACTOR 5; PROTEIN P21;

ARTICLE; CANCER CELL; CELL IMMORTALIZATION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMING CELL; CYTOPLASM; CYTOTOXICITY; DNA DAMAGE; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; THYROID CARCINOMA;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84859724485     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-21     Document Type: Article

References (22)

1. Battistini A. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J Interferon Cytokine Res 2009, 29:765-780. 10.1089/jir.2009.0030, 19929577.
2. Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 2008, 99:467-478. 10.1111/j.1349-7006.2007.00720.x, 18190617.
3. Barnes B, Lubyova B, Pitha PM. On the role of IRF in host defense. J Interferon Cytokine Res 2002, 22:59-71. 10.1089/107999002753452665, 11846976.
4. Manzella L, Conte E, Cocchiaro G, Guarniera E, Sciacca B, Bonaiuto C, Stagno F, Messina A. Role of interferon regulatory factor 1 in monocyte/macrophage differentiation. Eur J Immunol 1999, 29:3009-3016. 10.1002/(SICI)1521-4141(199909)29:09<3009::AID-IMMU3009>3.0.CO;2-H, 10508275.
5. Manzella L, Gualdi R, Perrotti D, Nicolaides NC, Girlando G, Giuffrida MA, Messina A, Calabretta B. The interferon regulatory factors 1 and 2 bind to a segment of the human c-myb first intron: possible role in the regulation of c-myb expression. Exp Cell Res 2000, 256:248-256. 10.1006/excr.1999.4794, 10739671.
6. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, Honda K, Taniguchi T. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A 2007, 104:3402-3407. 10.1073/pnas.0611559104, 1805533, 17360658.
7. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008, 26:535-584. 10.1146/annurev.immunol.26.021607.090400, 18303999.
8. Hu G, Barnes BJ. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J Biol Chem 2009, 284:2767-2777.
9. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001, 276:23382-23390. 10.1074/jbc.M101216200, 11303025.
10. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002, 21:2914-2918. 10.1038/sj.onc.1205459, 11973653.
11. Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 2003, 278:16630-16641. 10.1074/jbc.M212609200, 12600985.
12. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004, 279:45194-45207. 10.1074/jbc.M400726200, 15308637.
13. Fagin JA. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002, 16:903-911. 10.1210/me.16.5.903, 11981026.
14. Fagin JA. Perspective: lessons learned from molecular genetic studies of thyroid cancer-insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 2002, 143:2025-2028. 10.1210/en.143.6.2025, 12021165.
15. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2000, 11:1083-1089. 10.1023/A:1008322002520, 11061600.
16. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006, 66:4263-4272. 10.1158/0008-5472.CAN-05-3248, 16618750.
17. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003, 63:6424-6431.
18. Lin R, Yang L, Arguello M, Penafuerte C, Hiscott J. A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. J Biol Chem 2005, 280:3088-3095.
19. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002, 22:5721-5740. 10.1128/MCB.22.16.5721-5740.2002, 133975, 12138184.
20. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006, 12:1623-1629. 10.1158/1078-0432.CCR-05-2378, 16533790.
21. Hu G, Mancl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 2005, 65:7403-7412. 10.1158/0008-5472.CAN-05-0583, 16103093.
22. Couzinet A, Tamura K, Chen HM, Nishimura K, Wang Z, Morishita Y, Takeda K, Yagita H, Yanai H, Taniguchi T, Tamura T. A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci U S A 2008, 105:2556-2561. 10.1073/pnas.0712295105, 2268175, 18268344.